In recent months, Ozempic, the drug has become incredibly popular in the world of health and wellness. Its active ingredient, semaglutide, was approved by the FDA in 2017 and has changed the lives of thousands of people with type 2 diabetes. Not only does it help control blood sugar levels, but it has also proven to be highly effective for weight loss.
But now, a new discovery is raising red flags: researchers at Brigham and Women’s Hospital in Massachusetts found that those who take the drug may face a higher risk of developing a serious vision problem.
Ozempic, the Miracle Weight-Loss Drug, Could Leave You Blind — Here’s Why
The study revealed that patients with diabetes who take semaglutide were four times more likely to be diagnosed with a condition called non-arteritic anterior ischemic optic neuropathy (NAION). Even more alarming, individuals using the drug for obesity were seven times more likely to develop the condition compared to overweight patients who were not taking it.
Dr. Joseph Rizzo, one of the specialists leading the research, explained that NAION is a condition that can cause sudden and irreversible blindness, making the findings especially concerning.
Although the term sounds highly technical, NAION can be thought of as a sort of “mini stroke” in the optic nerve. Essentially, the blood vessels that supply the nerve stop functioning properly, damaging the crucial connection between the eye and the brain.
NAION is considered the most common cause of sudden vision loss in people over 50. While it is not frequent in the general population, when it does occur, the damage is permanent.
Although the study found a strong association, Dr. Rizzo clarified that he does not recommend patients stop their semaglutide treatments. That’s because the benefits in controlling diabetes and supporting weight loss are significant and have been shown to improve the quality of life for many people. Still, he emphasized the importance of caution: doctors and patients must be aware of the risk. When prescribing or using these medications, constant medical supervision and follow-ups are key.
Semaglutide remains a powerful tool in the treatment of diabetes and obesity, but like any drug, it is not without risks. This new discovery linking it to sudden vision loss opens the door for further research and a broader discussion on how to balance its benefits with its potential side effects. For now, the takeaway is not to panic—but to stay informed, remain cautious, and always consult with a doctor before making any decisions about its use.
